Category Archives: Patently BIOtech

Strong IP Protection is Critical Component of Trade Agreement

tpp

The next round of discussion on the Trans-Pacific Partnership (TPP) began yesterday in nearby Leesburg, VA.  The TPP currently includes eleven countries (Australia, Brunei, Canada, Chile, Malaysia, Mexico, New Zealand, Peru, Singapore, U.S. and Vietnam) and other countries in the region, such as Japan and Korea, may join in the future. The TPP will set an important precedent for global trade rules.  It is described by the U.S. Trade Representative as “an ambitious, 21st-century … Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

Preview: AUTM U.S. Licensing Survey: FY2011

044-btn

We’ve seen compelling evidence recently about the positive impact of university licensing activity. As we learned from “The Economic Contributions of University/Nonprofit Inventions in the United States: 1996-2010,” a report released by BIO in June, university/nonprofit licensing supported as many as 3 million “person years of employment.” Now there is even more good news to share. AUTM publishes a report of academic licensing activity at the end of each year for the prior fiscal year. Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO Voices Agree: Intellectual Property Delivers

Smethurst_Aaron

Over the last year, the U.S. Chamber of Commerce’s Global IP Center (GIPC) has met with entrepreneurs from around the world to get their personal stories on what it takes to become a breakthrough innovator in the 21st century. While the products that these innovators create come in many shapes and sizes, all of those we’ve come into contact with—many of whom from the annual BIO International Convention—have displayed a resounding respect for and interest Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

Novartis at India Supreme Court: Evergreening Myths and Patent Reality

Pine

Novartis will go before India’s Supreme Court on September 11, 2012 challenging the refusal by the Indian Patent Office to grant a patent on its cancer drug Glivec.  The Indian Patent Office rejected Novartis’ application under a provision in Indian law which is aimed at guarding against so called “patent evergreening.” BIO has written two posts deconstructing the myth of patent evergreening. 1.  Patent “Ever-Greening”: Novartis Confronts Patent Myth in India 2.  Patent Evergreening in Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

AMP v. Myriad: BIO Statement on Federal Circuit (Re)Decision

courtroom

BIO released the following statement on the Federal Circuit’s decision in the AMP v. Myriad case on remand from the Supreme Court to reconsider in light of Mayo v. Prometheus. “Today’s decision by the U.S. Court of Appeals for the Federal Circuit confirms long-standing law under which valuable DNA preparations, bacterial enzymes, plant-derived antibiotics and other industrially and medically useful substances can be considered for patenting. Such patents have long provided critical incentives for expensive Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,